AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03525821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: intranasal use of ketamine 1mg/kg with nitrous oxide
Study NCT00103779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40 (anti-huCD40 mAb)
Description: 1 mg/kg IV (in the vein) on Day 1; 1-2 mg/kg IV on Day 4; 2-4 mg/kg IV on Day 8; 3-8 mg/kg on Days 15, 22 and 29.
Study NCT00648544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Single-dose 80 mg oral immediate-release tablet
Study NCT00648544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Single-dose 80 mg oral immediate-release tablets
Study NCT04522362 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control task and Trier Social Stress Task
Description: Same as Arm
Study NCT04522362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control task and Trier Social Stress Task
Description: Same as Arm
Study NCT02322034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training
Description: Exercise training protocol (high intensity, interval training) is followed by the enrolled patients on hospital outpatient-based regimen 3 times/week for 24 weeks. The high intensity group will perform interval cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
Study NCT02283697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician AND an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the Dietary Approach to Stop Hypertension (DASH) diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
Study NCT02283697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control: Standard Care
Description: a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
Study NCT02390895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic repair of myelomeningocele before 26 SA
Description: prenatal minimally-invasive fetoscopic closure with iii) uterine exteriorization for a minimally-invasive repair under amniotic carbon dioxide insufflation iv) two trocars for the dissection and the cover with one patch or the suture of the skin edges by stitch
Study NCT00208091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin, type B
Description: Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
Study NCT02057406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2:1 EPA/DHA
Description: 400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams
Study NCT02057406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High EPA
Study NCT02057406 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02799511 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: protein expression
Description: Differential protein expression between the period of acute cerebral ischemia and the control period
Study NCT02330640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
Study NCT04187014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminocaproic Acid 1000Mg Tab
Description: Oral administration of a total 6 g of aminocaproic acid to reduce blood loss
Study NCT04187014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid tablets
Description: Oral administration of 3.9 g of tranexamic acid to reduce blood loss
Study NCT05609149 — intervention group
Intervention type: PROCEDURE
Intervention: total mesorectal excision
Description: patients must underwent total mesorectal excision
Study NCT00889460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBet v 1
Description: Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.
Study NCT00889460 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
Study NCT01223001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
Study NCT01223001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
Study NCT03769454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP-001
Description: PP-001 eye drops
Study NCT03769454 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops
Study NCT04049396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berberine
Description: 24 Patient consumed 6,25 g/day Berberine for 6 weeks
Study NCT02330640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
Study NCT02627391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early surgical aortic valve replacement
Study NCT02627391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Surgical aortic valve replacement
Study NCT01584752 — intervention group
Intervention type: PROCEDURE
Intervention: Gore-BioA Fistula Plug
Description: Gore-BioA Fistula Plug
Study NCT02586272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daifert
Study NCT02586272 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control Group
Study NCT03345095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marizomib
Description: Intravenous administration of Marizomib
Study NCT03345095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral Administration of Temozolomide
Study NCT03345095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Oral Administration of Temozolomide
Study NCT03345095 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 60 Gy in 30 fractions over 6 weeks
Study NCT03345095 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: 60 Gy in 30 fractions over 6 weeks
Study NCT04015505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for older adults: wisdom enhancement 'timeline technique'
Description: The intervention is comprised of five one-hour sessions of structured talking therapy, where participants create a timeline of their life with significant events included. Through dialogue with the therapist and structured worksheets, participants are encouraged to reflect on events in their life to recognise and develop qualities of resilience and self-compassion. They are then asked to use 'the wisdom of their years' to develop strategies to manage difficulties they are currently facing. Participants will also be asked to complete worksheets and try out new strategies between sessions.
Study NCT02330640 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: asprin
Description: All patients will be given asprin 100mg Qd within 24hours after operation,and will continue taking aspirin at the end of the study
Study NCT01829672 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography investigation
Description: 1x 20ml Ultravist (370mg J/ml)3-5ml/s, i.v.~1x 40ml Ultravist (370mg J/ml)3-5ml/s i.v. Contrast agent administration
Study NCT04365556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TASC Intervention
Description: All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
Study NCT01836445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keep It Up!
Study NCT01836445 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Knowledge Control
Study NCT03232502 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Description: Basic pharmacogenetic panel
Study NCT03659695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape Powder
Description: 69 g/d freeze dried grape powder
Study NCT03659695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: 69 g/d placebo powder matched for taste and appearance
Study NCT01657253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-148
Description: Instill 1 drop in each eye four times a day, for 60 days
Study NCT01657253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane
Description: Instill 1 drop in each eye four times a day, for 60 days
Study NCT03330106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.
Study NCT03330106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusion.
Study NCT03330106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion.
Study NCT03330106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous infusion.
Study NCT01416506 — intervention group
Intervention type: OTHER
Intervention: No Drug
Description: It's a surveillance
Study NCT03568760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semantic feature analysis
Description: Confrontation naming training and training in doing circumlocutions
Study NCT03568760 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comprehension training
Description: Reading and hearing comprehension
Study NCT02837016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable biofeedback
Study NCT02837016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Treatment
Description: group-based relaxation treatment based on mindfulness meditation principles
Study NCT02837016 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Treatment
Description: group-based relaxation treatment based on mindfulness meditation principles
Study NCT04172506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105
Description: Anti-PD-1 antibody
Study NCT02174120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Study NCT04180475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedRem application
Description: Medication adherence smartwatch application
Study NCT02174120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etomidate
Study NCT04044235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Cohort
Description: AGYW who are eligible for PrEP will be educated about the risk and benefits. For AGYW (aged 18-24 years) who consent to PrEP, an ART provider (nurse or clinician) certified by the MOH will provide PrEP (package of disoproxil fumarate/emtricitabine (Truvada)) on the same day that the client is determined eligible. Peer navigators will ensure linkage to facilities for follow-up care. The initial follow-up visit will occur one month from PrEP initiation to ensure that the client is tolerating the regimen and to answer any questions, with three-month follow-up visits thereafter.
Study NCT03748875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based relapse prevention
Description: mindfulness-based relapse prevention, 8 weeks
Study NCT04068220 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: intraoperative FVEPs monitoring
Description: During the surgery, a pair of goggles (similar to the swimming goggles) will be placed on patient's closed eyes. The goggles equipped with red LEDs will apply no pressure or minimal pressure on patient's closed eyes. Patient's left eye then right eye will be stimulated with flashing red light emitted by the goggles. Two subdermal needle electrodes will be placed under the skin behind patient's ears, and one subdermal needle electrode will be placed under the skin above the bridge of patient's nose. The two electrodes placed behind patient's ears, will record intraoperative flash visual evoked potentials (FVEPs) resulted from red light stimulation of patient's visual pathway through the eyes and the electrode above the bridge of the nose will record, at the same time, the activity of each eye's retina.
Study NCT03773081 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implantation of the Magmaris scaffold
Description: Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of one single ACS-causing de novo lesions in one separate major epicardial vessels is allowed.
Study NCT00935467 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin
Description: Tablets, oral, 2.5 mg, twice daily, 7 days
Study NCT04829864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP
Description: The program is offered by two facilitators to groups of three to seven women, in-person or online. The program is divided in three phases entitles Becoming a mother; A look at my own history and Looking ahead. The first phase aims to explore and normalize the emotions experienced by the participants in the course of their pregnancy and to support the use of healthy emotion regulation strategies. The second phase aims to support mentalization of trauma, by discussing the nature of trauma and its impact; by validating participants' feelings as understandable responses to trauma; by supporting a reflection on positive and harsh experiences with significant others and the ways both types of experiences influenced participants' mental states; and identifying how participants coped with trauma. In the last phase, discussions focus on participants' needs and strengths, on available resources to support resilience and envision positive and challenging moments with the child.
Study NCT02187185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sonicare/Elite-Flexcare Toothbrush
Description: Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles
Study NCT02187185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Toothbrush
Description: traditional (non-mechanical) toothbrush with nylon bristles and plastic handle
Study NCT01073553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin capsules (Optocef, BAYO5448 )
Description: Single dose of 500 mg (One 500 mg capsule)
Study NCT01073553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin capsules (Keflex)
Description: Single dose of 500 mg (Two 250 mg capsules)
Study NCT03140553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)
Description: TCH (docetaxel/carboplatin/trastuzumab) versus EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer
Study NCT03140553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)
Description: TCH (docetaxel/carboplatin/trastuzumab) versus EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer
Study NCT02056782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dociparstat sodium
Description: The following induction regimen was administered:~* Cytarabine (100 mg/m2/day) via continuous intravenous (IV) infusion 24 hours daily for 7 days.~* Idarubicin (12 mg/m2/day) IV on Days 1, 2, and 3.~* Dociparstat (4 mg/kg) given over 5 minutes IV, immediately after the idarubicin dose on Day 1, followed by a continuous IV infusion (0.25 mg/kg/hr for 24 hours daily) for a total of 7 days.
Study NCT02224040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone
Study NCT02224040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone and azithromycin
Study NCT02224040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin
Study NCT02224040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin and cefixime
Study NCT02689388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Use of femoral nerve block as part of general anesthesia
Study NCT02710422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Placement
Description: Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP, and before the urethrovesical anastomosis. The membrane will cut into two longitudinal pieces and it will be placed over each neurovascular bundle separately.
Study NCT02710422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPIC 26
Description: Participants will receive EPIC 26 psychosocial questionnaire at baseline, and post-RARP at protocol-defined intervals.
Study NCT02710422 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EPIC 26
Description: Participants will receive EPIC 26 psychosocial questionnaire at baseline, and post-RARP at protocol-defined intervals.
Study NCT02710422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSA Measurement
Description: Measurement of serum PSA levels every three months (+ 1 month) for first year post surgery, and then annually for 5 years.
Study NCT02710422 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PSA Measurement
Description: Measurement of serum PSA levels every three months (+ 1 month) for first year post surgery, and then annually for 5 years.
Study NCT03812549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients will receive treatment with Sintilimab 200mg every 3 weeks for a maximum of 24 months.
Study NCT03812549 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Radiation treatment utilized in this trial consists of SBRT with a standard doses to 30 Gy/3f
Study NCT03812549 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Radiotherapy
Description: LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 10 Gy/5f with conventional external beam radiation.
Study NCT03715504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-3654
Description: oral PIM inhibitor
Study NCT02433483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given by either intrathecal (IT) or intravenous (IV) route.
Study NCT02433483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triples
Description: given IT.
Study NCT02433483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPC-A
Description: Given IV.
Study NCT02037698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-PCI coronary CT scan
Description: Coronary CT scan before CTO PCI
Study NCT02198742 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miller blade
Description: To participate in the study the subjects must have >500 intubations with the miller blade.
Study NCT02198742 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Truview PCD
Description: Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable.